View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
November 2, 2018updated 01 Nov 2018 5:58pm

SHP647 may take a back seat to Entyvio after Takeda-Shire merger

On October 26th, Takeda announced that in its ongoing Phase I review of the proposed acquisition of Shire, discussions with the European Commission (EC) are underway in regards to the potential overlap in its inflammatory bowel disease (IBD) portfolio between Takeda’s anti-integrin biologic Entyvio (vedolizumab) and Shire’s Phase III candidate SHP647.

By GlobalData Healthcare

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

On 26 October, Takeda announced that in its ongoing Phase I review of the proposed acquisition of Shire, discussions with the European Commission (EC) are underway in regards to the potential overlap in its inflammatory bowel disease (IBD) portfolio between Takeda’s anti-integrin biologic Entyvio (vedolizumab) and Shire’s Phase III candidate SHP647.

Takeda commented that it remains committed to Entyvio, which is forecast by GlobalData to generate sales of just under $1.6bn in 2026 across the seven major markets (7MM – US, France, Germany, Italy, Spain, the UK, and Japan) for subcutaneous (SC) and intravenous (IV) formulations in IBD, marking a smart play by Takeda to prioritise the commercialisation of Entyvio.

Entyvio IV is currently marketed in more than 60 countries for ulcerative colitis (UC) and Crohn’s disease (CD), making it an established therapy in the IBD space. GlobalData estimates Entyvio IV alone will bring in sales of over $1.2bn in CD and UC across the 7MM in 2026. Entyvio SC is currently in Phase III development and is anticipated to launch as early as 2019.

Shire’s SHP647 is being developed as an SC formulation, and key opinion leaders (KOLs) interviewed by GlobalData have indicated it will compete with Entyvio, but are uncertain if it will hold efficacy benefits. SHP647 is forecast to launch in 2023, four years after the launch of Entyvio SC, leaving little room for the former in an already established biologic market space. If not differentiated from Entyvio, GlobalData anticipates Takeda will look to license or fully divest SHP647, turning the company’s full attention to Entyvio in the IBD biologic space.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology